These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

634 related items for PubMed ID: 25607753

  • 1. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, Miyoshi S, Kanazawa S, Toyooka S.
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [Abstract] [Full Text] [Related]

  • 2. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 3. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.
    Exp Cell Res; 2014 May 01; 323(2):288-96. PubMed ID: 24631288
    [Abstract] [Full Text] [Related]

  • 4. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.
    Mol Cancer Res; 2009 Oct 01; 7(10):1736-43. PubMed ID: 19808904
    [Abstract] [Full Text] [Related]

  • 5. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
    Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S.
    J Thorac Oncol; 2012 Jul 01; 7(7):1078-85. PubMed ID: 22592212
    [Abstract] [Full Text] [Related]

  • 6. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 7. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 8. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M, Xia S, Zhuang L, Han N, Chu Q, Chao T, Peng P, Chen Y, Gui Q, Yu S.
    Int J Oncol; 2013 Jun 01; 42(6):2094-102. PubMed ID: 23588221
    [Abstract] [Full Text] [Related]

  • 9. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
    Kim EJ, Jeong JH, Bae S, Kang S, Kim CH, Lim YB.
    J Cell Biochem; 2013 Jun 01; 114(6):1248-56. PubMed ID: 23592446
    [Abstract] [Full Text] [Related]

  • 10. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
    Zhang S, Zheng X, Huang H, Wu K, Wang B, Chen X, Ma S.
    Oncotarget; 2015 Mar 20; 6(8):5832-45. PubMed ID: 25714021
    [Abstract] [Full Text] [Related]

  • 11. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Mar 15; 18(6):1663-71. PubMed ID: 22317763
    [Abstract] [Full Text] [Related]

  • 12. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
    Hong YS, Jang WJ, Chun KS, Jeong CH.
    Oncol Rep; 2014 Jun 15; 31(6):2619-24. PubMed ID: 24789511
    [Abstract] [Full Text] [Related]

  • 13. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF, Harrison LR, Mironov A, Roberts RA, Dive C.
    J Thorac Oncol; 2010 Jun 15; 5(6):765-77. PubMed ID: 20421816
    [Abstract] [Full Text] [Related]

  • 14. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC.
    Cancer Chemother Pharmacol; 2010 Jul 15; 66(2):381-8. PubMed ID: 19921194
    [Abstract] [Full Text] [Related]

  • 15. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
    Hashida S, Yamamoto H, Shien K, Miyoshi Y, Ohtsuka T, Suzawa K, Watanabe M, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.
    Cancer Sci; 2015 Oct 15; 106(10):1377-84. PubMed ID: 26202045
    [Abstract] [Full Text] [Related]

  • 16. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
    Wang YQ, Shen AJ, Sun JY, Wang X, Liu HC, Zhang MM, Chen DQ, Xiong B, Shen JK, Geng MY, Zheng M, Ding J.
    Acta Pharmacol Sin; 2016 Dec 15; 37(12):1587-1596. PubMed ID: 27616574
    [Abstract] [Full Text] [Related]

  • 17. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun 15; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 18. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS, Oh B, Lee MH, Nam KY, Jin HR, Yang H, Choi J, Kim SW, Lee DH.
    Cancer Lett; 2016 Mar 01; 372(1):75-81. PubMed ID: 26723875
    [Abstract] [Full Text] [Related]

  • 19. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M, Lv S.
    Mol Med Rep; 2015 Apr 01; 11(4):2767-74. PubMed ID: 25483995
    [Abstract] [Full Text] [Related]

  • 20. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM, Chen JT, Chiu CH, Lai CL, Hsiao SY, Chang KT.
    Lung Cancer; 2013 Nov 01; 82(2):305-12. PubMed ID: 24055492
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.